首页 | 本学科首页   官方微博 | 高级检索  
     

急性肺栓塞溶栓疗效及溶栓前后NT-proBNP的变化
引用本文:王淑红,段志荣,周强,裴瑞泽,黄琼,刘建敏,袁义强. 急性肺栓塞溶栓疗效及溶栓前后NT-proBNP的变化[J]. 临床心血管病杂志, 2012, 0(9): 696-698
作者姓名:王淑红  段志荣  周强  裴瑞泽  黄琼  刘建敏  袁义强
作者单位:郑州市第七人民医院急诊科;安阳市人民医院心内科
摘    要:
目的:观察瑞替普酶对急性肺栓塞(APE)患者溶栓治疗的临床疗效及溶栓前后血浆N端B型尿钠肽前体(NT-proBNP)水平的变化及其临床意义。方法:42例符合溶栓治疗条件的APE患者给予瑞替普酶18mg+18mg静脉溶栓治疗,分别观察溶栓前及溶栓6h后患者临床表现、血浆NT-proBNP、肌钙蛋白T(cTnT)水平,溶栓12~24h复查超声心动图、CT肺动脉成像或核素肺灌注显像,评价临床疗效。结果:血管再通患者37例(88.1%),其NT-proBNP浓度和肺动脉压力均较溶栓前显著下降[(8 672.4±201.7)pg/ml︰(1 559.8±23.5)pg/ml,(52.82±17.34)mmHg︰(38.13±12.32)mmHg,1mmHg=0.133kPa;均P<0.01)],且NT-proBNP浓度下降幅度与肺动脉压下降幅度、右心室/左心室比值密切相关(r分别为0.61、0.54);溶栓前后cTnT水平差异无统计学意义。血管未通患者5例,其溶栓前后NT-proBNP、cTnT及肺动脉压力差异无统计学意义。结论:瑞替普酶对APE患者进行静脉溶栓治疗有较好的临床疗效和安全性,且动态检测NT-proBNP浓度可作为评价溶栓再灌注成功与否的有效指标。

关 键 词:肺栓塞,急性  瑞替普酶  溶栓治疗  N端B型尿钠肽前体

The therapeutic efficacy of thromblysis and NT-proBNP changes in patients with acute pulmonary embolism
WANG Shuhong,DUAN Zhirong,ZHOU Qiang,PEI Ruize,HUANG Qiong,LIU Jianmin,Yuan yiqiang. The therapeutic efficacy of thromblysis and NT-proBNP changes in patients with acute pulmonary embolism[J]. Journal of Clinical Cardiology, 2012, 0(9): 696-698
Authors:WANG Shuhong  DUAN Zhirong  ZHOU Qiang  PEI Ruize  HUANG Qiong  LIU Jianmin  Yuan yiqiang
Affiliation:1(1Department of Cardiology,Zhengzhou 7th People’s Hospital,455000,Zhengzhou,China;2Emergency Department,Anyang People’s Hospital)
Abstract:
Objective:To evaluate the efficacy of thrombolytic therapy with reteplase,and investigate the clinical significance of detecting N terminal pro brain natriuretic peptide(NT-proBNP) changes in patients with acute pulmonary embolism(APE). Method:Forty two patients with documented APE recieved thrombolytic therapy with reteplase.Clinical manifestations,plasma NT-proBNP and cardiac troponin T(cTnT) levels were monitored before and 6 h after thrombolytic therapy.Echocardiography and pulmonary CT angiography or radionuclide lung perfusion imaging were performed to evaluate the therapeutic efficacy 12-24 h after thrombolytic therapy. Result:Thirty seven patients(88.1%) exhibited significant angiographic reperfusion after thrombolytic therapy.NT-proBNP level and mean pulmonary arterial pressure decreased significantly in all of them [(8 672.4±201.7)pg/ml︰(1 559.8±23.5)pg/ml,(52.82±17.34)mmHg︰(38.13±12.32)mmHg,1 mmHg=0.133 kPa;both P<0.01)].Plasma NT-proBNP levels had a positive correlation with pulmonary arterial pressure and RV/LV ratio(r=0.61,0.54).There was no significant variation in cTnT levels after thrombolytic therapy.While there was no significant improvement in levels of NT-proBNP,cTnT and pulmonary arterial pressure in five failed thromblysis patients after thrombolytic therapy. Conclusion:Thrombolytic therapy with reteplase is effective and safe for APE.Serial measurements of NT-proBNP could be used as a effective indicator to assess the success or failure of the thrombolytic treatment.
Keywords:pulmonary embolism,acute  reteplase  thrombolytic therapy  N-terminal pro-brain natriuretic peptide
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号